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PRODUCTION OF FUNCTIONALLY ENHANCED  
 
MONOCLONAL ANTIBODIES VIA GENE THERAPY 
 
AARON EDWARDS 
ABSTRACT 
 While the last century of medical discoveries has made a significant impact on 
improving the lives of human populations across the globe, a perfect solution to the 
yearly infection cycle from the influenza virus has yet to be discovered. Although 
vaccines stand the best chance at targeting yearly epidemics, new treatment options must 
be created to combat the arrival of rapidly mutating and antiviral-resistant strains of the 
virus that could lead to another pandemic such as the 1918 Spanish flu that killed 
millions worldwide. We describe a method to create functionally enhanced monoclonal 
antibodies targeting influenza via genetic engineering of fragment crystallizable glycan 
structures. Muscle and liver cell lines were lentivirally-transduced to produce the broadly 
neutralizing antibody, Fi6v3, while also overexpressing a critical glycosylation enzyme, 
B-1,4-N-acetyl-glucosaminyltransferase III. Secreted antibodies were tested for effector 
functionality using a Natural Killer cell degranulation assay and an antibody-dependent 
cellular phagocytosis assay. Results conclude that modified antibodies from both muscle 
and liver cells lines exhibit enhanced function in comparison to their unmodified 
counterparts, providing support to the future creation of an influenza prophylactic or 
treatment option using antibodies with the ability to more effectively activate innate 
immune killing mechanisms.   
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INTRODUCTION 
Despite the availability of numerous antivirals and vaccines, infection by the 
influenza virus continues to have a substantial impact on human lives worldwide. Severe 
infections caused by yearly epidemics, usually starting in November and lasting until 
March, lead to an estimated 250,000 to 500,000 deaths globally (CDC 2010). In just three 
of the most recent influenza pandemics, infection cycles that lead to significantly higher 
rates of disease than yearly epidemics, total mortality can be estimated at 50-100 million 
people (Lambert and Fauci 2010).  Of these fatalities, 90% were from elderly populations 
that are known to have markedly reduced vaccine-induced protection against influenza 
(Goodwin 2006). Although vaccination is still the best approach for prevention and 
control of the virus and usually produces an effective neutralizing antibody response in a 
significant portion of the population, the occurrence of antiviral-resistant and rapidly 
mutating viral strains that outpace current vaccination production schedules highlights the 
urgent need for alternative treatment strategies (de Jong 2005; Hurt 2009; Monto 2006). 
Work is underway across the globe to improve the efficacy and cost of current 
therapeutics while simultaneously developing novel forms of treating infection and 
preventing future pandemics from occurring.  
Influenza Biology 
Influenza types A and B are enveloped RNA viruses belonging to the 
Orthomyxoviridae family. While both types lead to annual epidemics, only type A has 
been linked to the more severe pandemic infection cycles (Zimmer 2010). Both virus 
types contain two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), 
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that are components of the membrane of the viral envelope. HA, divided into a variable 
head region (HA1) and a highly conserved stem/stalk region (HA2), facilitates binding to 
host cells via sialic acid receptors, thus leading to membrane fusion between virus and 
host (Wang 2011). Neuraminidase enables new viral progeny to be released from the host 
cell, promoting spread of the virus from host to the surrounding uninfected cells. 
Influenza A is classified into 17 different subtypes based on their HA protein (H1-H17) 
and further subdivided into two distinct phylogenetic groups, group 1 and group 2. Only 
H1, H2, and H3 are known to have taken residence in the human population. Influenza B 
is classified into a mere two distinct phylogenetic lineages, Victoria and Yamagata 
(Yamashita 1988).  
Current Vaccine Obstacles 
An ideal influenza vaccine would be expected to provide long-lasting protection 
against a wide variety of subtypes. However, even when formulated to include the entire 
virus, current vaccines tend to elicit antibody responses targeting the highly variable HA1 
head region and are often strain specific (Fiore 2012). This unfavorable response leads to 
the need to generate entirely new formulations year to year depending on the dominating 
virus strain and lead to a weakened or lack of response entirely against rapidly mutating 
strains not included in the cocktails. When influenza viruses generate either novel 
subtypes through mutation or were simply not predicted by vaccine manufacturers in time 
to generate an effective product, the lack of population-wide immunity can lead to 
pandemics such as the 1918 Spanish Flu (Ahmed 2007). High costs are also associated 
with the production of pathogen needed to make vaccine formulations, but are expected 
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to be sold at low cost to the consumer, further complicating vaccine production (Zimmer 
2010). Without more insights into how future vaccines can be rapidly and inexpensively 
generated while also conferring proper immune responses targeting multiple or novel 
subtypes of influenza, it is evident that other methods of combatting future pandemics 
must be explored.  
Influenza Antivirals 
 When vaccines do not effectively confer protection against severe influenza 
infection in an individual, the mainstream treatment option is to give the patient 
antivirals. Two classes of influenza antivirals are currently approved for use in countries 
across the world: adamantanes, which inhibit viral replication by obstructing an ion 
channel crucial for viral uncoating once inside a host cell (Aoki 1998), and 
neuraminidase inhibitors (NAIs), which bind to NA and prevent viral progeny from being 
released from infected cells (Hurt 2006). Unfortunately, rapid selection of drug resistant 
viruses by antivirals has led to 100% of currently circulating influenza viruses showing 
resistance to adamantanes, leaving only NAIs for effective treatment and prophylaxis (Oh 
and Hurt 2014). While little resistance has been seen against current NAIs, the ongoing 
concern that drug-resistant mutants will emerge is an extremely motivating factor for 
researchers to come up with alternative treatment strategies to target the rapidly changing 
virus.    
Monoclonal Antibody Therapy 
One alternative method to treat influenza that has been actively explored during 
the 21st century is monoclonal antibody therapy. Touted as either a complementary 
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strategy to current antivirals or as a treatment alone, its usage to combat a variety of 
medical conditions including viral diseases is well established (Sawyer, 2000). Although 
sufficient to provide protection from infection, monoclonal therapy in its current form 
can come with a high price tag and its intravenous administration is much more invasive 
than an intramuscular or intranasal vaccine. With respect to influenza, monoclonal 
antibodies could be used against strains that are resistant to antivirals or in the case of 
terminal patients with severe cases of the disease. In case of future pandemics caused by 
highly pathogenic viruses, prophylactic administration of monoclonals could be essential 
for those at high risk of infections such as the elderly, immunocompromised, healthcare 
workers, and others most liable to spread the infection further (Laursen and Wilson 
2014).  
Broadly Neutralizing Antibodies 
Recent work developing monoclonals targeting influenza has led to the discovery 
of antibodies that are capable of neutralizing a breadth of viral strains (Corti 2011). One 
such broadly neutralizing antibody (bNAb), Fi6v3, shows cross-reactivity unlike those 
elicited via most vaccinations, enabling it to react with all 17 HA subtypes. This 
extraordinary spectrum of binding is achieved by targeting the more conserved stalk 
region of the virus’ hemagglutinin protein, HA2, keeping the head region from 
undergoing the necessary conformation changes needed to enter the host cell. Promising 
results shown in numerous animal models highlights the potential for bNAbs to become a 
more mainstream option for those seeking alternative treatment for influenza infection or 
	  5 
a prophylactic option to prevent further spread of the disease at the population level 
(Laursen and Wilson 2014; Balazs 2013; Simmons 2007; Itoh 2014).     
Antibody Effector Functions  
Although recognition of an invading microbial pathogen by the Fab region (see 
Figure 1) of an antibody is essential for neutralization, antibodies are able to initiate other 
effector functions to tackle the pathogen through interactions with its Fc region. One such 
mechanism, antibody dependent cellular cytotoxicity (ADCC), is initiated when a 
specific isotype of Fc receptors (FcγRs) on Natural Killer (NK) cells, specifically 
FcγRIIIA, is activated by IgG antibodies and signal release of cytotoxic molecules to 
subsequently destroy the antibody coated cell (Ravetch and Bolland 2001; Nimmerjahn 
and Ravetch 2008). Another mechanism of killing, antibody dependent cellular 
phagocytosis (ADCP), commences when the other isotypes of FcRs on phagocytic innate 
immune cells such as monocytes and macrophages are activated, leading to ingestion and 
degradation of the pathogen inside intracellular phagosomes. While these mechanisms 
have been well characterized in vitro, many studies over the last decade have shown that 
Fc-mediated effector functions play an important role in providing protection against 
numerous pathogens in vivo (Delilo 2014; Abboud 2010; Bournazos 2014; Schmitz 
2012). This realization holds true in the case of influenza as well. Mice that were given 
serum from H1N1-immunized mice showed an explicit requirement for interactions with 
FcγRs for protection against infection (Huber 2001) and these FcγRs were shown to 
possibly mediate protection by the bNAb HA stalk-targeting, Fi6v3 (Corti 2011; DiLillo 
2014). The exact mechanisms that are needed for HA-specific antibodies to confer 
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protection against influenza in vivo remains controversial, but finding ways to enhance 
these critical cellular mechanisms may provide further insight into how scientists can 
better combat future pandemics through utilization of monoclonal antibody for therapy 
and/or prophylaxis.   
Antibody Glycan Engineering 
Not only has the monoclonal therapeutics field made widespread advances when 
it comes to discovering and improving broadly neutralizing antibodies, but it has also 
done significant work into enhancing their binding and effector functions as well. By 
genetically engineering the pathway in cells that is responsible for the post-translational 
addition and/or modification of oligosaccharides located on the Fc portion of antibodies, 
also known as Fc glycans (Figure 1, yellow), in vitro techniques have successfully been 
able to tune and modify critical effector functions linked to known antibody glycan 
patterns (Chan 2010). Although these glycans consist of only four variable sugar subunits 
(fucose, galactose, N-Acetylglucosamine (GlcNAc), and N-Acetylneuraminic (sialic) 
acid), the presence or absence of these subunits has been shown to have a significant 
effect on an antibody’s function (Figure 2a)(Varki 1993). The most common technique 
for altering these antibody glycans is by overexpressing or knocking out specific enzymes 
known to be important in the glycosylation pathway located in the ER and golgi 
apparatus. A significant focus on enhanced functionality via glycan tailoring has been 
geared towards the treatment of B cell malignancies, with the glycoengineered CD20-
targeting antibody, obinutuzumab, showing superior ADCC and ADCP activity 
compared to non-glycoengineered forms (Golay 2013; Mossner 2010). These 
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enhancements observed in vitro correlated with prolonged patient survival in a recent 
phase 3 clinical trial studying the use of obinutuzumab in patients with chronic 
lymphocytic leukemia (CLL) (Goede 2014). 
Glycan Modification 1: Fucose 
 One glycan modification that has garnered the most attention when it comes to 
glycoengineered therapeutics is that of core fucose (Figure 2a, red triangle). Enzymatic 
addition of fucose by alpha1,6 fucosyltransferase (FUT8) to the core glycan structure has 
been shown to reduce the ADCC activity of an antibody by as much as 50-fold when 
compared to its afucosylated counterpart (Shields 2002; Peipp 2008; Natsume 2005; 
Shinkawa 2003). Increased affinity of FcγRs, specifically FcγRIIIA, for afucosylated Fcs 
has been speculated as the reason for such enhanced function (Shields 2002). By utilizing 
cell lines specifically lacking the FUT8 enzyme, it is possible to generate antibody glycan 
structures that are completely afucosylated and demonstrate enhanced ADCC (Yamane-
Ohnuki 2004). In the search for better influenza therapeutic and treatment options, FUT8-
knockout cell lines could prove to be a beneficial tool to create more effective influenza 
antibodies.  
Glycan Modification 2: Bisecting GlcNAc 
Another glycan modification that has been observed to alter antibody effector 
functions is that of the presence of a bisecting GlcNAc (Figure 2a, blue square). While 
absence of fucose on glycan structures can mediate enhanced function, it is the enzymatic 
addition of bisecting GlcNAcs, via the enzyme B-1,4-N-acetyl-glucosaminyltransferase 
III (GnTIII or MGAT3), that some attribute to improved ADCC and FcγR binding in 
	  8 
vitro (Umana 1999). Since the addition of the GlcNAc occurs upstream to that of fucose 
in the glycosylation pathway, several groups suggest that GlcNAc blocks activity of 
FUT8, preventing fucose addition via steric hindrance, and thereby enhancing ADCC 
(Schacter 1986; Umana 1999). Modulation of MGAT3 expression levels to enhance 
effector functionality could be another vital technique to apply towards the creation of  
future influenza therapeutics.  
Project Overview 
The aim of this project was to apply techniques used to improve monoclonal 
therapeutics for oncology treatment and determine if the same principles can yield a 
functionally enhanced influenza antibody that could lead to a next generation 
prophylactic or therapeutic. We hypothesized that overexpression of GnTIII (MGAT3), 
known to direct bisecting, afucosylated glycan structures and also known to enhance 
effector functionality of antibodies treating B cell malignancies, could lead to similar 
enhancements when producing the broadly neutralizing influenza antibody, Fi6v3. 
Previous work in our lab found correlations between effector functionality and particular 
antibody glycan structures/components (with both glycan analyses and functional testing 
done in-house), which led to the creation of the heat map shown in Figure 2b. While the 
figure was created using human serum samples versus antibodies from cell lines, in the 
case of this study, it should still be an extremely valuable tool as we proceed through the 
spectrum of functional assays. Therefore, we hypothesize that it is possible to do the 
following with the current study: 1) create cell lines expressing the antibody, Fi6v3, and 
overexpressing the glycosylation enzyme, MGAT3; 2) analyze glycans on the cell line-
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produced antibodies; 3) predict effector functionality using our lab’s previously 
determined structure-function correlations (Figure 2b); and 4) perform the array of in 
vitro assays to confirm correlative predictions. When taken to completion, this work 
would be the first of its kind to generate functionally enhanced monoclonal antibodies 
against influenza via glycan modification.    
 
	  10 
 
 
 
   
Figure 1. Structural Model of an Immunoglobulin. Heavy chains can be seen in blue, 
light chains in red. The Fc glycan can be seen in yellow.  
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Figure 2. Glycan Structure and Functional Correlation Heat Map. a) Symbolic 
representation of a complex immunoglobulin glycan structure b) Heat map highlighting 
which antibody glycan structures correlate with various effector functions. Fucose 
(circled red triangle); Bisecting GlcNac (circled blue square); Mannose (green circles); 
Galactose (yellow circles); Sialic acid (purple diamonds). G0, G1, and G2 represent the 
number of galactose residues on the glycan.  
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METHODS 
Sequence Maps: 
 Sequences for the plasmid constructs used in this study were compiled and 
presented using Geneious R7 software (Biomatters) (Figures 4-9).  
Fi6v3 IgG Antibody:  
The DNA fragment encoding the broadly neutralizing antibody, Fi6v3, was 
designed based on the work done by Corti 2011. Modified to include a furin site between 
the heavy and P2A linker (Figure 3), this version eliminates extra glycosylation sites that 
can be present on the Fc region of the antibody. The fragment was designed and 
purchased from Invitrogen and was received in a pMK-RQ backbone vector (Figure 4).     
hMGAT3 protein: 
 The DNA fragment encoding the codon-optimized human beta-1,4-N-
acetylglucosaminyltransferase (GnTIII or MGAT3) was purchased from Invitrogen and 
was received in a pMA-RQ backbone vector (Figure 5).   
Lentiviral Plasmid Construction: 
Sequences for Fi6v3 and hMGAT3 were cloned into fluorescent lentiviral vector 
constructs, pLVX-IRES-ZsGreen1 (Clontech; Figure 6) and pLVX-IRES-mCherry 
(Clontech; Figure 7) respectively, using standard molecular techniques. Briefly, 5 ug of 
each vector were digested using 1uL each of FastDigest EcoRI, NotI, and XbaI (Thermo) 
for 4 hours 37°C to ensure complete digestion. To reduce self-ligation, 5’ ends were 
dephosphorylated using Calf Intestinal Phosphatase (CIP) (NEB). 5 μl CIP enzyme was 
added for every 100 μl of digestion solution, incubated at 37°C for 1 h, and then 
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inactivated at 65°C for 30 min. The digested, dephosphorylated vector was run on a 1% 
agarose gel (Sigma) with 10 μl of SYBR® Safe DNA Gel Stain (Life Technologies) at 
200V using standard electrophoresis equipment. Using a Red® gel imaging machine 
(Proteinsimple) to visualize the DNA, bands corresponding to the vector were extracted 
and purified using a QIAquick Gel Extraction Kit (Qiagen). Ligations of the respective 
inserts and vectors were performed at a molar ratio of 1:3 vector to insert with the 
following components: 2 ul of 10X T4 DNA Ligase buffer (NEB), 50 ng of vector DNA, 
37.5 ng insert DNA, 1 ul T4 DNA Ligase (NEB), and nuclease-free water up to 20 ul 
(Invitrogen). The ligation reactions were incubated at room temperature for 2 hours. After 
incubation, ligation was chilled on ice for 5 minutes and 5 uL of each were added into 50 
uL of TOP10 competent cells (Life Technologies) to begin transformation procedure. 
Competent cell/DNA mixture was placed on ice for 30 minutes before being placed into a 
42°C water bath for 45 seconds to undergo heat shock. The mixture was then placed back 
on ice for 5 minutes. 300 uL of SOC media (Life Technologies) was added to the 
cell/DNA mixture and placed in a 37°C incubator to grow for 2 hours. Varying volumes 
of the grown bacteria were plated onto 10cm LB agar plates (Corning) containing 
ampicillin (Sigma) and incubated once again at 37°C, this time overnight. Colonies were 
picked, grown overnight in 250mL of ampicillin-containing LB (Sigma), and then 
extracted using a Plasmid Maxi Kit (Qiagen). Plasmid DNA was quantified using a 
NanoDrop 8000 (Thermo) according to manufacturer’s instructions. DNA was sent to 
sequencing to confirm proper construction, and plasmid maps were made upon successful 
completion (Figures 8 and 9).         
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Plasmid Digestion and Gel Electrophoresis: 
 The sequences encoding our vectors, inserts, and vectors plus inserts were 
digested with FastDigest EcoRI, NotI, and XbaI (Thermo) for 1 hour at 37°C. Ten 
microliters of the digestions were run alongside a 1kb plus ladder (Life Technologies) on 
a 1% agarose gel (Sigma) with 10 μl of SYBR® Safe DNA Gel Stain (Life 
Technologies) at 100V for 90 minutes using standard electrophoresis equipment. The gel 
was then read using a Red® gel imaging machine (Proteinsimple).      
Cell Culture: 
All cell lines were obtained from American Tissue Culture Collection (ATCC) 
and maintained in regular conditions at 37°C in 5% CO2 in medium containing penicillin 
(100 U/mL) and streptomycin (100 U/mL) (Corning). C2C12 mouse myoblasts (ATCC 
number CRL-1772), Hepa 1-6 (ATCC number CRL-1830), and 293T/17 (ATCC number 
CRL-11268 were grown in Dulbecco’s Modified Eagle’s Medium (Sigma) containing 
10% Fetal Bovine Serum (Gibco) and L-Glutamine (584 mg/L) (Corning).  
Recombinant Lentivirus Production and Concentration: 
LV particles were produced by transient transduction of 293T/17 cells with a 
packaging plasmid (psPAX2; Addgene), a plasmid encoding the viral envelope 
(pMD2.G; Addgene), and the vector itself (pLVX.IRES.ZsGreen.hFi6v3 or 
pLVX.IRES.mCherry.hMGAT3). Respectively, 3.35 ug, 1.65 ug, and 5 ug of each 
plasmid were transduced using PerFectin™ Reagent (Genlantis) according to 
manufacturer’s instructions. After 48 hours, culture medium was concentrated using 
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LentiX Concentrator (Clontech) according to manufacturer’s instructions and 
immediately used for cell transduction. 
Cell Transduction: 
 All transduction conditions were tested in triplicates. The day prior to 
transduction, 100000 Sp2/0 cells per well were plated in a 12-well plate and 200000 
C2C12 and Hepa1-6 cells were plated in a 6-well plate. Virus was diluted in culture 
medium with 4 ug/mL of polybrene (Sigma) and added to the well to a final volume of 
either 0.5 mL/well for the 12-well plate or 1mL/well for the 6-well plate. Plates were 
spun in a countertop centrifuge at 800g for 1.5 hours at 32 °C before being placed into 
incubator overnight. Cells were passaged and maintained in culture for 1 week before 
sorting and any analysis was performed in order for all non-integrated transgene copies to 
be eliminated. The double positive line was first transduced with Fi6v3, grown for a week 
to confluency, and then transduced with hMGAT3.  
Flow Cytometry: 
 Cells from each cell line were washed with 1X PBS (Corning), trypsinized with 
0.25% trypsin-EDTA (Gibco), neutralized with Dulbecco’s Modified Eagle’s Medium 
(Sigma) containing 10% Fetal Bovine Serum (Gibco), washed again with 1X PBS 
(Corning), and then fixed in 100uL of 4% paraformaldehyde (Sigma). Flow cytometry 
was performed using a BD LSRFortessa 5 Laser system and FACSDiva software was 
used for initial data collection. FloJo (Tree Star) was used to analyze collected data and 
compile quadrant figures showing percentages of each fluorescent protein using negative 
controls to properly gate populations.  
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Cell Sorting: 
 Seven days after transduction, adherent cells were detached using 0.25% trypsin-
EDTA (Gibco), harvested and washed in 1X phosphate buffer saline (PBS) (Corning) one 
time. Cells were then given to the Ragon Institute Sorting Facility and were sorted for 
either ZsGreen single-positive (Fi6v3) or ZsGreen/mCherry double-positive (Fi6v3 and 
hMGAT3) fluorescence (FACSAria; BD bioscience).  
Western Blot Analysis:  
 One million cells from each line (C2C12, C2C12.Fi6v3, C2C12.Fi6v3.hMGAT3, 
Hepa1-6, Hepa.Fi6v3, Hepa.Fi6v3.hMGAT3) were washed with 1X PBS (Corning), 
trypsinized with 0.25% trypsin-EDTA (Gibco), neutralized with Dulbecco’s Modified 
Eagle’s Medium (Sigma) containing 10% Fetal Bovine Serum (Gibco), washed again 
with 1X PBS (Corning), and lysed using 300 uL of M-PER Mammalian Protein 
Extraction Reagent (Thermo) and 1000X protease inhibitor (Sigma). Lysed cells were 
spun at full speed in a tabletop centrifuge at 4°C. Protein supernatant concentrations were 
determined using a BCA (bicinchoninic acid) Protein Assay Kit (Thermo) according to 
manufacturers instructions. Twenty ug of each sample were denatured and reduced with 
10X Bolt™ Sample Reducing Agent (Life Technologies) and 4X Bolt™ LDS Sample 
Buffer (Life Technologies) at 95°C for 8 minutes. Samples were run alongside an 
Odyssey® fluorescent molecular weight ladder (LI-COR) through a Bolt™ 4-12% Bis-
Tris Precast Protein Gel (Life Technologies) at 200V for 35 minutes in a Bolt™ Mini Gel 
Tank (Life Technologies). Bolt™ MES SDS Running Buffer (Life Technologies) was 
used during the electrophoresis. Gel was transferred to a nitrocellulose membrane using 
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iBlot® dry transfer stacks and system (Life Technologies) according to manufacturers 
instructions. The membrane was blocked for 2 hours at room temperature using 15 mL of 
Odyssey™ Blocking Buffer (LI-COR). After blocking, primary antibodies probing for 
hMGAT3 (Rb ab103427; Abcam) and GAPDH (loading control) (Ms ab8245; Abcam) 
were diluted in 10 mL of the same blocking buffer at 1:500 and 1:1000, respectively, and 
incubated with the membrane overnight. The membrane was washed six times with 
0.05% PBS-Tween 20 for 5 minutes each. Secondary IRDye® antibodies targeting 
mouse and rabbit monoclonal primary antibodies (Donkey host; LI-COR) were incubated 
with the membrane at a 1:15000 dilution in new blocking buffer for 45 minutes at room 
temperature. Membrane was washed as previously described. The membrane was read 
using an Odyssey® CLx Infrared Imaging System (LI-COR) and corresponding Image 
Studio™ software according to manufacturers instructions. In order to see appropriate 
bands, the red channel, which included the molecular weight ladder, was intentionally 
overexposed.  
ELISA for IgG Antibody Quantification: 
 All immunoglobulin quantifications were determined using a Human IgG total 
Ready-SET-Go!® kit (eBioscience) according to manufacturer’s instructions. Briefly, a 
96 well ELISA plate (Corning) was coated overnight at 4°C with purified anti-human 
IgG in provided coating buffer. Wells were washed twice with 400 μl/well of standard 
wash buffer, allowing one minute of soaking time in between washes. Wells were 
blocked with 250 μl of provided blocking buffer for 2 hours at room temperature (RT). 
Wells were aspirated and washed as previously described. Provided recombinant human 
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IgG standard was diluted as instructed and added alongside samples at 100 μl per well. 
The plate was incubated for two hours at RT and subsequently washed as before for a 
total of four washes. Detection antibody, HRP-conjugated anti-human IgG, was added to 
each well at 100 μl/well for 1 hour at RT and then washed four times. Substrate solution, 
Tetramethylbenzidine (TMB), was added to each well at 100 μl for 5-10 minutes at RT. 
2N H2SO4 was used to stop the developing when appropriate and plates were read at 450 
nm using an Infinite m1000 (Tecan).   
ELISA for Antigen-Specific Antibody Quantification: 
 A 96 well ELISA plate (Corning) was coated overnight at 4°C with 100ul of 
1ug/mL of influenza hemagglutinin (HA) [(H1N1), A/Brisbane/59/2007; Immune 
Technologies]. Wells were washed twice with 400 μl/well of standard wash buffer, 
allowing one minute of soaking time in between washes. Wells were blocked with 250 μl 
of provided blocking buffer for 2 hours at room temperature (RT). Wells were aspirated 
and washed as previously described. 100 uL of each sample were added to the plate. 
Diluted concentrations of HIVIG (NIH) were used to create a standard curve. The plate 
was incubated for two hours at RT and subsequently washed as before for a total of four 
washes. Detection antibody, HRP-conjugated anti-human IgG, was added to each well at 
100 μl/well for 1 hour at RT and then washed four times. Substrate solution, 
Tetramethylbenzidine (TMB), was added to each well at 100 μl for 5-10 minutes at RT. 
2N H2SO4 was used to stop the developing when appropriate and plates were read at 450 
nm using an Infinite m1000 (Tecan). Quantifications were calculated and displayed in 
correlating binding of the positive control, HIVIG.         
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Glycosylation pattern analysis: 
Cell supernatant collection/concentration: 
C2C12, Hepa1-6, and Sp2/0 cell lines stably producing Fi6v3 +/- hMGAT3 were 
grown in 5-layer cell culture flasks (Falcon®) at ATCC-recommended seeding densities 
using a total of 150 mL per flask of DMEM containing 10% Ultra-Low IgG FBS (Gibco). 
Supernatant was collected after seven days, spun at 400g for 5 minutes to remove 
residual cells, and subsequently concentrated using 50kD Amicon Ultra-15 centrifugal 
filter units (Millipore) according to manufacturer instructions. Concentration was 
repeated 3 times in the same unit before being quantified via ELISA. Additional 
concentrations were performed until desired antibody concentrations were reached.  
Antibody preparation: 
Glycan analysis was performed based on methods developed in house. Fifty 
micrograms of concentrated supernatant containing Fi6v3 was purified overnight using 5 
μl of protein G coated magnetic beads (Millipore) that were pre-washed twice with 200 
μl of PBS (Corning). Purified antibody was washed five times with PBS to remove 
residual supernatant and all unbound proteins. A DynaMag™-2 Magnet (Life 
Technologies) was used to immobilize beads during all wash steps. The bound antibody 
was then placed in 20 μl of PBS at 4°C until further processing. 
Digestion/Separation of IgG into Fab and Fc fragments: 
The 20 μl of purified and washed antibody-bead complex was placed into a 96 
well PCR plate and digested into bound-Fc and unbound-F(ab’)2 fragments using 5U 
(0.075 μl) of IdeS (Immunoglobulin G-degrading degrading enzyme of S. pyogenes, 
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Genovis) for 1 hour at 37°C. After IdeS digestion was complete, 80 μl of PBS was added 
and the 100 μl total sample was placed back into the magnet for 5 minutes to pellet beads. 
The supernatant fraction containing unbound-F(ab’)2 fragments was removed. The bead-
bound fraction containing desired Fc and any incompletely digested IgG were washed 
twice in 200 μl of PBS and brought up in 18 μl of PBS or water. 
Removal of N-glycan from protein: 
Once Fc was prepared, glycans were released from protein using enzymatic 
digestion with Peptide-N-Glycosidase F (PNGase F, New England Biolabs). Protein was 
denatured using 2 μl of the provided denaturation buffer and incubated at 95°C for 10 
minutes. Samples were cooled on ice before the addition of 4 μl of provided G7 digestion 
buffer, 4 μl of 10% NP-40, 0.25 μl PNGase and water to a total volume of 40 μl. 
Reaction mixture was incubated at 37°C for 30 minutes. 
To separate released glycans from protein, 200 μl of ice-cold ethanol was added 
to each well.  Plates were incubated for ten minutes at -20°C and precipitated protein was 
pelleted by centrifugation at 2700x g for ten minutes. Glycan containing supernatants 
were transferred to fresh plates and dried completely in a Labconco centrivap and then 
kept at -20°C until labeling and cleanup were ready to be performed.  
Labeling and clean-up of free glycan: 
Thoroughly dried glycans were labeled by reductive amination using 2 μl of a 1:1 
mixture of 25mM 8-aminopyrene-1,3,6-trisulfonic acid, APTS (Life Technologies) in 
1.2M citric acid and 1M sodium-cyanoborohydrate in THF (Sigma Aldrich). Plates were 
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sealed tightly and the reduction reaction proceeded protected from light at 55°C for 3 
hours. 
To remove unreacted dye, fresh size exclusion columns were prepared by 
pipetting 250 μl of 50% P2 gel slurry (BioRad) to the wells of an 96 well empty filter 
plate (Harvard Apparatus) and the column was packed by centrifugation at 750xg for 1 
minute and washed with 100 μl of ultrapure water. Fluorescently labeled glycans were 
resuspended in 60 μl of ultrapure water and applied directly to the top of the packed size 
exclusion columns in the filter plate. These were spun at 750xg for two minutes and the 
flow-through contained the labeled glycan. Glycans were stored at 4°C until analysis on a 
DNA sequencer. 
Running and analysis of glycan: 
A 1:10 dilution and full concentrated portion of the 50 ug sample was transferred 
into a PCR plate and loaded onto a 3130XL ABI DNA sequencer. Parameters for run are 
as described in LaRoy 2006 using POP7 polymer in a 36cm capillary. Acquisition 
software was set to export data as .fsa files. 
Identification of glycan peaks and analysis of glycan proportions: 
After electrophoresis run, exported .fsa data files were converted to .xml using 
conversion software provided by Applied Biosystems 
(http://www.appliedbiosystems.com/absite/us/en/home/support/software-
community/tools-for-accessing-files.html). Converted files were analyzed using matlab to 
align peaks and calculate the area under the curve for each peak. 
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Although all possible antibody glycan structures were identified using this 
method, we only present fucose and bisecting GlcNAc moieties.  
Antibody Dependent Cellular Phagocytosis Assay: 
The ADCP assay was performed based on methods produced by (Ackerman 
2011) (see Figure 10). THP-1 cells were purchased from ATCC and cultured as 
recommended. Care was taken to keep cultures at cell densities below 0.5×106/ml in 
order to maintain consistent levels of FcγR expression and assay performance. Flu 
hemagglutinin (HA) [(ΔTM)(H1N1), A/Brisbane/59/2007; Immune Technologies] was 
biotinylated on lysine residues using a sulfo-NHS LC biotin reagent (Thermo Scientific, 
21935) according to the manufacturer's instructions. Biotinylated antigen was incubated 
with 1 μm fluorescent neutravidin beads (Invitrogen, F8776) overnight at 4°C. Beads 
were subsequently spun down and washed twice in PBS-BSA in order to remove excess 
unbound antigen, and then resuspended at a final dilution of 1:100 in PBS-BSA. Antigen-
coated beads were stored for up to a week at 4°C prior to use. Saturation of the beads was 
determined experimentally, via incubation with differing amounts of antigen. Bead 
coating conditions that gave the maximal phagocytic score in conjunction with a control 
monoclonal antibody were used. 9×105 beads (equivalent of 0.1 μl of supplied 
suspension, or 10 μl of the dilution described above) were placed in each well of round 
bottom 96 well plate. Antibodies were added to each well and the plate was incubated for 
a 2 hours at 37°C in order to allow antibodies to bind to the beads. Following 
equilibration, 2×104 THP-1 cells were added to each well in a final volume of 200 μl, and 
the plate was incubated overnight under standard tissue culture conditions. The next day, 
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half the culture volume was removed and replaced with 100 μl of 4% paraformaldehyde 
before plates were analyzed by flow cytometry on a BD LSR II equipped with an HTS 
plate reader. Samples were mixed thoroughly (100 μl mix volume, repeated three times), 
prior to analysis of 30 μl of each sample, yielding at least 2,000 cell events per sample. A 
phagocytic score was determined by gating the samples on events representing cells, and 
calculated as follows: (% bead positive × MFI bead positive, or integrated MFI (Darrah 
2007)).  
NK Cell Activation ELISA and Intracellular Cytokine Staining: 
An ELISA assay to determine the expression of surface CD107a and intracellular 
production of IFN-γ and MIP-1β (Figure 11) was performed by coating a 96-well ELISA 
plate (Fisher Nunc) with 300 ng/well of HA(H1N1) (A/Brisbane/59/2007) (Immune 
Technologies). Cell culture supernatant containing 25 ug of Fi6v3 was added to the well 
and incubated at 37°C for 2 hours. NK cells were isolated from whole blood from healthy 
donors using negative selection with RosetteSep (STEMCELL Technologies), as 
recommended by the manufacturer. Isolated primary NK cells, anti–CD107a–
phycoerythrin (PE)–Cy5 (BD), brefeldin A (10 μg/ml) (Sigma), and GolgiStop (BD) 
were then added to the plate for 5 hours at 37°C. The cells were then first stained for 
surface markers using anti–CD16–allophycocyanin (APC)–Cy7 (BD), anti–CD56-PE-
Cy7 (BD), and anti–CD3–Alexa Fluor 700 (BD) and then stained intracellularly with 
anti–IFN-γ–APC (BD) and anti–MIP-1β–PE (BD) using Fix and Perm A and B solutions 
(Invitrogen). The cells were then analyzed using flow cytometry as previously described. 
NK cells were defined as CD3-negative and CD16- and/or CD56-positive.   
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Figure 3. Optimization of Fi6v3 Antibody Glycosylation Site. Addition of a furin  
between the heavy and P2A linker can be seen in pink. Removal of unwanted 
glycosylation sites can be seen in the optimized antibody representation.   
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Figure 4. Plasmid Map of Fi6v3 Antibody in pMK-RQ Vector. Purchased from 
Invitrogen. Restriction sites for NotI and XbaI flank the antibody insert.  
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Figure 5. Plasmid Map of hMGAT3 in pMA-RQ Vector. Purchased from Invitrogen. 
Restriction sites for NotI and XbaI flank the protein insert.  
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Figure 6. Plasmid Map of Lentiviral Fluorescent Vector pLVX.ZsGreen. Purchased 
from Clontech. Restriction sites for EcoRI, NotI, and XbaI are denoted at the top of the 
figure.  
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Figure 7. Plasmid Map of Lentiviral Fluorescent Vector pLVX.mCherry. Purchased 
from Clontech. Restriction sites for EcoRI and NotI are denoted at the bottom-right of the 
figure.  
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Figure 8. Plasmid Map of pLVX.ZsGreen.Fi6v3 Lentiviral Construct. Restriction 
sites for NotI, EcoRI, and XbaI flanking the inserted antibody (bottom-right yellow) are 
denoted.  
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Figure 9. Plasmid Map of pLVX.mCherry.hMGAT3 Lentiviral Construct. 
Restriction sites for NotI, EcoRI, and XbaI flanking the inserted protein sequence 
(bottom-right blue) are denoted.   
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Figure 10. Overview of an Antibody-Mediated Cellular Phagocytosis Assay.  
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Figure 11. Overview of a Natural Killer Cell Degranulation Assay.  
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RESULTS 
Digestion of Lentiviral Plasmids 
 In order to confirm that the lentiviral plasmids with our inserts of choice were 
constructed successfully, they were digested with EcoRI, NotI, and XbaI, and subsequent 
digestions were run on an agarose gel alongside the appropriate pLVX vector and 
corresponding insert (which came in their own empty vectors) (Figure 12). Bands 
analogous to appropriate vector and insert can be seen for both pLVX.ZsGreen.Fi6v3 and 
pLVX.mCherry.hMGAT3 (See plasmid maps in Figures 10 and 11 for exact segment 
sizes). Bands corresponding to the pLVX.Zsgreen vector can be seen in columns 2 and 3. 
Bands corresponding to the Fi6v3 insert can be seen in columns 2 and 4. The Fi6v3 band 
in column 4 is brighter than that in column 2 because the original insert came in an empty 
vector that was similar in size as the insert. Column 6-8 show similar results, only with 
the hMGAT3 insert and vector. The pLVX.mCherry vector backbone can be seen as a 
band around 9 kb in columns 6 and 7. The hMGAT3 insert can be seen in columns 6 and 
8. Unlike the original Fi6v3 plasmid, the hMGAT3 insert came in a vector backbone that 
was not the same size as the insert, so two bands are clearly visible post digestion. 
Confirmation of proper construction allowed us to proceed to the transduction of cell 
lines.  
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Figure 12. Digestion of Lentiviral Constructs and Original Insert Plasmids. 500 ng 
of each plasmid were digested with FastDigest EcoRI, NotI, and XbaI for 1 hour at 37°C. 
Electrophoresis was run on a 4-12% Bis-Tris gel at 100V for 90 minutes. Lanes from left 
to right: 1) Ladder; 2) pLVX.ZsGreen.Fi6v3; 3) pLVX.ZsGreen; 4) pMK-RQ.Fi6v3; 5) 
Ladder; 6) pLVX.mCherry.hMGAT3; 7) pLVX.mCherry; 8) pMA-RQ.hMGAT3. 
 
Expression of Surface Markers on Transduced Cell Lines 
 Flow cytometry was performed on the transduced cell lines in order to confirm 
successful lentiviral insertion (Figure 13). Negative controls were used to gate cells and 
calibrate for auto-fluorescence. Cell populations were seen in appropriate quadrants for 
ZsGreen/GFP (Fi6v3), mCherry (hMGAT3), or both. Expression level of GFP/Fi6v3 in 
the C2C12.Fi6v3 line was 99%. C2C12.Fi6v3.hMGAT3 was double positive in almost 
96% of cells analyzed. Hepa.Fi6v3 was at a lower end 67% positive. 
Hepa.Fi6v3.hMGAT3 were 78% double positive. Encouraging flow results from all cell 
lines allowed us to proceed to sorting in order to use cell lines that have maximized 
expression of the inserts and for future analyses to be most effective. 
  1         2       3        4       5        6        7        8 
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Figure 13. Transgene Expression as Detected by Flow Cytometry. X-axis 
(ZsGreen/GFP) corresponds to Fi6v3 antibody expression and Y-axis (mCherry) 
corresponds to MGAT3 expression. a) C2C12.Fi6v3; b) C2C12.Fi6v3.hMGAT3; c) 
Hepa.Fi6v3; d) Hepa.Fi6v3.hMGAT3.  
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Alternative Confirmation of hMGAT3 Overexpression 
 In an attempt to confirm overexpression of hMGAT3 in lentiviral-transduced cell 
lines, a western blot was performed using 20 ug of lysates from each line (Figure 14). 
Primary antibodies used to probe for MGAT3 and GAPDH (loading control) were 
incubated with the membrane overnight. Secondary IR antibodies were used that 
fluoresce either red (MGAT3) or green (GAPDH) and can be clearly seen in the figure. 
Against the expected outcome, bands corresponding to MGAT3 could be identified in all 
cell lines and not just those positive for our overexpression insert.    
 
                            
 
Figure 14. hMGAT3 Expression as Detected By Western Blot Analysis. Each cell line 
was lysed, reduced, and denatured, and 20ug was loaded into each well. Bands at 61 kDa 
represent MGAT3 while bands at 41 kDa represent the loading control, GAPDH. 
Columns are as follows: 1) molecular weight marker (LI-COR); 2) C2C12.Fi6v3; 3) 
C2C12.Fi6v3.hMGAT3; 4) Hepa.Fi6v3; 5) Hepa.Fi6v3.hMGAT3.  
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Human Immunoglobulin G ELISA 
 An IgG ELISA was performed to confirm that not only were the cell lines 
producing the proper fluorescent protein, as confirmed via flow cytometry, but that they 
also produced the inserted antibody (Figure 15). Quantifications were obtained by 
running an IgG standard alongside of samples and creating a standard curve that could be 
used to convert OD values into immunoglobulin concentrations. Successful secretion, 
between 30 and 60 nanograms of antibody per 100 uL of loaded supernatant, was seen 
across all cell lines. 
 
   
Figure 15. Human Immunoglobulin G ELISA on Lentiviral Cell Line Supernatants. 
100 uL of each lentiviral cell line supernatant were assayed using the Human IgG total 
Ready-SET-Go!® kit (eBioscience). Measurements are in nanograms of antibody per 
well. Cell lines were all positive for Fi6v3 and labeled on figure as those with or without 
hMGAT3 modification.   
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Influenza Specific Antibody Functional ELISA  
 Once the IgG ELISA showed positive secretion of antibody, a functional assay 
was necessary to ensure that they could bind to the appropriate influenza protein. Results 
shown in Figure 16 showed that all secreted antibody bound to pre-coated hemagglutinin 
protein. Quantifications were made by running dilutions of HIVIG alongside samples and 
creating a standard curve of binding concentrations. Three of four samples were in the 
15-40 ng/mL of HIVIG binding range, while Hepa.Fi6v3 showed an unexpectedly 
superior binding at 160 ng/mL.    
 
   
Figure 16. Influenza-Specific ELISA on Cell Line Supernatants. 100 uL of each 
lentiviral cell line supernatant was loaded into wells containing pre-coated influenza 
hemagglutinin (HA) protein. IgG-HRP was used as a detection antibody. TMB was used 
to develop. Measurements are in nanograms per milliliter of HIVIG (used as a positive 
control) binding. Cell lines were all positive for Fi6v3 and labeled on figure as those with 
or without hMGAT3 modification.     
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Immunoglobulin Fc Glycosylation Analyses 
 The functionally predictive antibody glycosylation patterns from each cell line 
were characterized via in house methods described previously. Decreased fucose and 
increased bisecting GlcNAc structures, both predictive of enhanced effector function (see 
Figure 4), could be seen for both cell types (Figures 17 and 18).  The C2C12 line 
overexpressing MGAT3 produced antibody glycans with a 20% decrease in fucose levels 
and a 152% increase in bisected GlcNAc moieties compared to that produced by 
C2C12.Fi6v3 (Figure 17). The Hepa1-6 line overexpressing MGAT3 produced antibody 
glycans with a 23% increase in fucose levels and a 58% increase in bisected GlcNAc 
moieties in comparison to those produced by Hepa.Fi6v3 (Figure 18).  
  
Figure 17. Immunoglobulin Glycan Analysis of Fucosylated Structures. A novel in-
house glycan analysis method based on capillary electrophoresis was performed as 
described on lentiviral cell line-produced antibodies. Analysis shown is based on glycan 
structures exhibiting fucose. Levels are shown as percent of overall fucosylated glycans. 
Cell lines were all positive for Fi6v3 and labeled on figure as those with or without 
hMGAT3 modification. 
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Figure 18. Immunoglobulin Glycan Analysis of Bisected GlcNAc Structures. A novel 
in-house glycan analysis method based on capillary electrophoresis was performed as 
described on lentiviral cell line-produced antibodies. Analysis shown is based on glycan 
structures exhibiting bisected GlCNAc. Levels are shown as overall percent bisected. 
Cell lines were all positive for Fi6v3 and labeled on figure as those with or without 
hMGAT3 modification. 
 
 
Immunoglobulin Effector Function Analyses 
A phagocytosis assay (ADCP) was performed on the antibodies to see if the 
MGAT3 modification enhanced this particular effector function. As predicted by Figure 
4, no discernable effect was seen when comparing antibodies made in MGAT3-
overexpressed cell lines to that of cell lines only expressing Fi6v3 (Figure 19).  
In order to determine if our modified antibodies actually exhibited enhanced 
function as predicted by Figure 4, an NK activation assay was performed that has been 
shown to correlate tightly with NK cell cytokine production and cytotoxicity (Alter 
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2004). This assay was performed in place of ADCC due to time constraints, but was still 
expected to show increases across the board as indicated in Figure 4. As expected, an 
increase in all activation markers was detected in samples containing antibodies from our 
MGAT3-overexpressed cell lines in comparison to those only expressing the antibody 
construct (Figure 20). The C2C12 line overexpressing MGAT3 produced antibodies that 
showed increases of 154%, 60%, and 15% of CD107a, IFN-g, and MIP-1B levels, 
respectively. The Hepa1-6 line overexpressing MGAT3 produced antibodies that showed 
increases of 20%, 62%, and 57% of CD107a, IFN-g, and MIP-1B levels, respectively. 
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Figure 19. Antibody-Dependent Cellular Phagocytosis Assay. 0.78 ug of concentrated 
antibody from lentiviral-transduced cell lines were added to pre-biotinylated antigen 
bound to fluorescent neutravidin beads for 2 hours at 37°C. Following equilibration, 
2×104 THP-1 cells (monocytes) were added to each well and incubated overnight at 
37°C. Flow cytometry was used to analyze cells. A phagocytic score was determined by 
gating the samples on events representing cells, and calculated as follows: (% bead 
positive × MFI bead positive, or integrated MFI). Cell lines were all positive for Fi6v3 
and labeled on figure as those with or without hMGAT3 modification.         
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Figure 20. Natural Killer Cell Degranulation Assay. 25 ug of concentrated antibodies 
from lentiviral-transduced cell lines were added to wells pre-coated with 300 ng of 
purified hemagglutinin protein for 2 hours. Isolated primary NK cells along with an 
inhibition cocktail were added and incubated for 5 hours at 37°C. The cells were then 
stained for surface and intracellular markers and subsequently analyzed by flow 
cytometry. NK cells were defined as CD3-negative and CD16- and/or CD56-positive. 
Cell lines were all positive for Fi6v3 and labeled on figure as those with or without 
hMGAT3 modification.    
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DISCUSSION 
 
 Our results are the first of its kind to show production of monoclonal antibodies 
targeting influenza that were functionally enhanced via glycan engineering strategies. 
The first of the functional assays we performed, antibody-dependent cellular 
phagocytosis (ADCP) (Figure 19), supported previous work completed by our lab 
demonstrating that bisected GlcNAc structures do not enhance ADCP (Figure 2b). If 
conclusions were to be drawn from the results, it is that the modification actually trended 
towards decreasing phagocytic activity when compared to antibodies with unmodified 
glycans. Modified C2C12-produced antibodies generated a phagocytic score 18% lower 
than its unmodified counterpart, and modified Hepa1-6-produced antibodies generated a 
15% lower score compared to its respective unmodified counterpart. The reduction is too 
low, and also without experimental replicates, to make conclusions as to why this 
difference was observed. More work to reveal the link between specific glycan structures 
and ADCP needs to be carried out before futher conclusions can be reached from this 
data. Regardless, the trend seen between our samples with increased bisecting GlcNAc 
and faintly lower ADCP fell in line with our lab’s previous work to predict functional 
outcomes based on glycan structures, giving more power to the correlation heat map as 
we explore additional assays using our modified antibodies.  
While the enhanced NK degranulation created via hMGAT3 overexpression was 
seen across muscle and hepatocyte cell lines, it was unexpectedly the muscle cell line that 
seemed to be most amenable to modification. Since glycosylation plays a critical role in 
the secretion of proteins, we had hypothesized that hepatocytes would be more amenable 
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to glycosylation alterations due to their inherent secretory capacity compared to muscle. 
However, bisection of glycans on C2C12.hMGAT3-produced antibodies jumped 152% 
compared to only 58% in the Hepa1-6.hMGAT3 line. Since both cell lines were sorted 
post-transduction and flow analysis, their expression of hMGAT3 should have been at 
similar levels, eliminating the possibility of varied overexpression efficiencies. The 
increases in bisection led to the NK degranulation assay showing CD107a levels 
skyrocketing 154% in antibodies produced in MGAT3-modified muscle cells compared 
to only 20% in the hepatocyte line, providing a solid link between the bisection and 
function. It is important to note that the Hepa.hMGAT3 antibodies produced higher 
increases in IFN-g and MIP-1B than that of C2C12.hMGAT3. However, while the other 
two markers are indicators of activation, they play a secondary role to that of CD107a 
(Alter 2004). Though the link between structure and function when it comes to bisection 
was affirmed by the NK degranulation results, it is clear that more work needs to be done 
to evaluate the amenability of glycan tailoring and functional enhancements across tissue 
types and whether or not certain lines may be better candidates for those looking for 
specific functional outcomes and also in future studies in general focused on the range of 
glycan modifications.    
Another interesting observation made from the NK degranulation results was that 
the enhanced functionality post modification seemed independent of fucose levels. 
Modified C2C12 antibody fucose levels dropped only 20% while exhibiting a 152% 
increase in bisection and a 154% increase in CD107a, but fucose on antibodies modified 
in Hepa1-6 cells dropped a comparable 23% and only exhibited a 58% bisection increase 
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and 20% CD107a spike. This result supports work done by Umana 1999 and Lifely 1995 
showing that GlcNAc bisection can affect ADCC in a fucose independent manner. 
However, it is contradictory to more recent work suggesting that non-fucosylation is the 
most important structural element for increased FcgammaRIIIa affinity, leading to 
increased ADCC (Shinkawa 2003). If fucose was the most important structure for 
determining ADCC activity in our study, its percent change after modification should 
have mirrored the CD107a levels more than that of bisection. However, our results 
indicate that bisection more closely mirrored functional enhancement and was the most 
influential glycan element for this study, giving support to previous work showing 
fucose-indpendent functional enhancement. Our results also contradict the assertion that 
MGAT3-induced GlcNAc bisection completely blocks the addition of fucose to glycans 
(Schacter, 1986), as similar percentage drops in fucose across cell lines could not be 
traced back to the same percentage increase in bisection. These findings highlight the 
need to more clearly define the role fucose plays in the enhancement of this particular 
antibody’s functionality, as it is possible that fucose’s role in functional killing 
mechanisms may vary depending on the modification used and anitbody selected for 
enhancement. To explore this issue futher, we have already begun work to create Fi6v3-
producing cell lines lacking FUT8, the enzyme responsible for fucose addition. 
Comparisons between the antibodies produced by the two cell lines will allow us to 
determine which of the two most popular modifications works best for influenza specific 
anitbody enhancement.  
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As mentioned previously, recent work by DiLillo 2014 concluded that protection 
against influenza in vivo via broadly neutralizing antibodies depends on its binding 
location on the circulating virus’ HA protein. They established that antibodies targeting 
the conserved stalk region, such as Fi6v3, most certainly require Fc receptor-mediated 
killing to confer protection in vivo while those targeting the variable head region do not. 
This finding suggests that work to enhance antibody effector functions needs to focus not 
only on the pathogen being bound/neutralized, but also the method and location in which 
it binds to said pathogen. This conclusion may suggest that applicable glycan 
enhancements for influenza therapeutics may be target-specifc and antibody-specific, 
requiring production and tailoring methods unique to each. Future studies should include 
a broadly neutralizing antibody that binds to the variable head region to see what the 
same modifications do in comparison to that of our enhanced Fi6v3. 
Although many other routes can be taken with this project, our immediate plans 
are to produce more replicates of the previously performed experiments while also 
completing the characterization of the other effector functions elicited by the modified 
antibodies. It is important to note that results seen from this study are from experiments 
performed only once, as we were limited by the amount of antibody available upon initial 
collection. Full characterization of the effector functionality needs to be completed so 
that when the pathogen-neutralizing mechanism most relevant for protection against 
influenza in vivo becomes evident, the best glyco-tailoring methods, targets, and how 
they affect each function will have been more clearly defined. ADCC is known to 
important mechanism for in vivo protection against leukemia, but the same may not be 
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true for that of influenza. Ferrara 2006 also showed that while overexpression of MGAT3 
was sufficient to produce enhanced ADCC, it was necessary to simultaneously 
overexpress another golgi resident enzyme, ManII, in order to increase other killing 
mechanisms, such as antibody-dependent complement deposition (ADCD). Taken 
together, it seems that while work to determine which killing mechanism in vivo is most 
critical for protection, the discovery of additional glycosylation targets and/or 
combinations may be needed in order to produce antibodies that exhibit the largest 
breadth of functional enhancements.  
Future work is also ongoing to take this proof-of-concept glycoengineering 
strategy targeting influenza in the direction of a nucleic acid-based therapeutic. Geall 
2012 showed that it was possible to use non-viral based delivery of self-amplifying RNA 
to express an immunogenic antigen in mice. Eliminating possible safety issues when 
using pDNA (recombination) or viral delivery (oncogenic activation) while also 
providing evidence that immune responses could be generated from their RNA-encoded 
antigen, they took giant steps towards developing a new nucleic acid based vaccine 
strategy. We want to build on that work by creating self-amplifying RNA encoding Fi6v3 
and hMGAT3 (or a miRNA targeting FUT8) to see if we can provide another means of 
immunoprophylaxis against influenza via an enhanced antibody. While work done by 
Balazs 2013 showed that it is possible to provide antibody-mediated protection against 
influenza via viral vectored gene transfer, their method requires an undesirable permanent 
insertion into the genome. If successful, this work could be used to provide rapid and 
transient immunity against influenza using broadly neutralizing antibodies targeting a 
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breadth of predicted strains instead of relying on the unpredictable antigen-based immune 
training employed by current vaccines. 
Until then, this proof-of-concept study has shown that it is possible to generate 
cell lines producing a functionally-enhanced, broadly neutralizing antibody against 
influenza. Immunocompromised populations that cannot generate their own immune 
responses or even eldery patients not always protected by vaccines could benefit 
immensely from a potential therapeutic using these methods. While the future application 
of such knowledge could be taken in many other directions, the reality of rapidly 
mutating viruses, out-of-date vaccine manufacturing practices, and high costs of current 
monoclonal therapeutics are only a few of the glaring concerns forcing the scientific 
community to discover and optimize methods of treating infectious disease and other 
human ailments. By enhancing antibody effector functions via glycan modifications, 
future work based on studies such as these could lead to methods that increase efficacy 
and decrease the cost of next generation therapeutics and vaccines.  
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